Status:
UNKNOWN
Comparison of the Efficiency of Two Different PPI Formula in Atypical GERD
Lead Sponsor:
Taipei Veterans General Hospital, Taiwan
Conditions:
Compare the Response Rate of Atypical GERD After PPI Therapy
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
Patients with atypical gastro-esophageal reflux disease (GERD), include cough, globus, and non-cardiac chest pain (NCCP) usually require more aggressive or double dose proton pump inhibitor (PPI) thera...
Detailed Description
We conduct a prospective randomized study since July 2017 after IRB approval. Patients between the ages of 20 and 80 years presenting to the gastroenterology outpatient clinic for atypical GERD sympto...
Eligibility Criteria
Inclusion
- atypical GERD symptoms (cough, globus, or NCCP)
- with or without typical GERD symptoms (heartburn or acid regurgitation)
- A total Reflux Symptom Index (RSI) score ≥13
Exclusion
- Patients who currently took pro-kinetic agents, baclofen, antacid, sucralfate, histamin-2 receptor antagonists, PPI, antitussive, non-steroid anti-inflammatory drugs, anxiolytics, or anti-depressants during screening and during study period
- Patients who have severe cardiac, pulmonary, hepatic, or renal diseases
- Patients who have uncured underlying malignancy
- Patients with laryngeal or pharyngeal disorders
- Patients with a history of gastrointestinal (GI) surgery, symptoms of GI tract obstruction
- Patients with a contraindication for PPI use
Key Trial Info
Start Date :
August 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03418337
Start Date
August 1 2017
End Date
December 1 2018
Last Update
February 1 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Veterans General Hospital
Taipei, Taiwan, 11217